NeutralLOW severityHealthcare & Pharma4d ago

H.C. Wainwright initiates Liquidia stock with buy rating

H.C. Wainwright initiates Liquidia stock with buy rating — $LQDA one-month chart
$LQDA daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Liquidia trades near the middle of its 52-week range, with recent coverage concentrated in the last week but mostly neutral. The stock closed down 1.22% at $57.41, while the Health Care sector shows calm today.

Written by Wook AI Nov 14, 1:55 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about LQDA. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · liquidiaEvent risk Low

Nothing reported about liquidia across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 78% a year
Now $55.98Week $49.81–$62.15 (±11.0%)Month $43.33–$68.63 (±22.6%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
  • How the stock is trading: $LQDA -0.69% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.

Where the stock stands

Liquidia ($LQDA) slipped 0.69% to $55.98 in the latest session. Over the past month it is up 64.0%. It now sits 40% under the 52-week high of $93.61 and 151% above the year's low of $22.31. The year's high was 4.2 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 10, 2026), $LQDA lost $236.3M over the quarter to Sep 30, 2026 on revenue of $225.3M (+31.2% QoQ). Operations brought in $279.9M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $248.9M. Total liabilities were $708.4M against $396.1M of cash on Sep 30, 2026. Liabilities of $708.4M exceeded assets of $682.9M on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 10, 3 days before this story; it is $LQDA's own account and the first thing to read. Figures are as filed with the SEC; the $LQDA page has the full statements.

How much coverage it is getting

Wook has filed 3 stories on Liquidia in the last 30 days, 1 of them this week. That is a little busier than usual: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 3 neutral and 0 bearish. This one reads neutral too, in line with most of them. This is the only one from Investing.com; the rest came from other outlets.

The bigger picture

In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $LQDA page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $LQDA: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 13, 2026. $LQDA has moved -3.48% ($58.00 to $55.98). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy